August 8, 2007 – Accuray Inc. announced that use of its CyberKnife Robotic Radiosurgery System to noninvasively treat extracranial tumors has increased 75 percent in 2007.
The number of lung cancer patients treated with the system doubled, while the number of prostate cancer procedures with the system quadrupled over the past year.
Radiosurgery has historically been used exclusively for the treatment of brain tumors. The CyberKnife System, however, is FDA cleared to treat tumors anywhere in the body, including the spine, lungs, prostate, liver and pancreas.
Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment, the company says. This enables the CyberKnife System to deliver precise, high-dose radiation, minimizing damage to surrounding healthy tissue and eliminating the need for invasive head or body stabilization frames.
“The CyberKnife System has revolutionized cancer care. We are now able to treat a wide array of tumors, including many that were untreatable in the past," said Dr. Greg Gagnon, associate professor, interim chairman of the Department of Radiation Medicine and CyberKnife Program Director at Georgetown University Hospital in Washington, DC. "Because it is noninvasive and delivers high-dose radiation with sub-millimeter accuracy, the CyberKnife System is a perfect tool for destroying tumors quickly with minimal side effects."
For more information: www.accuray.com.
August 09, 2024 
